219 related articles for article (PubMed ID: 16396760)
41. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
42. Prodromal myeloproliferative neoplasms: the 2008 WHO classification.
Kvasnicka HM; Thiele J
Am J Hematol; 2010 Jan; 85(1):62-9. PubMed ID: 19844986
[TBL] [Abstract][Full Text] [Related]
43. Influence of the assays of endogenous colony formation and serum erythropoietin on the diagnosis of polycythemia vera and essential thrombocythemia.
Mossuz P;
Semin Thromb Hemost; 2006 Apr; 32(3):246-50. PubMed ID: 16673278
[TBL] [Abstract][Full Text] [Related]
44. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.
Rudzki Z; Sacha T; Stój A; Czekalska S; Wójcik M; Skotnicki AB; Grabowska B; Zduńczyk A; Okoń K; Stachura J
Int J Hematol; 2007 Aug; 86(2):130-6. PubMed ID: 17875526
[TBL] [Abstract][Full Text] [Related]
45. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
46. Pediatric Myeloproliferative Neoplasms.
El-Sharkawy F; Margolskee E
Clin Lab Med; 2021 Sep; 41(3):529-540. PubMed ID: 34304780
[TBL] [Abstract][Full Text] [Related]
47. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.
Thiele J; Kvasnicka HM; Zankovich R; Diehl V
Haematologica; 2000 Nov; 85(11):1126-34. PubMed ID: 11064463
[TBL] [Abstract][Full Text] [Related]
48. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology.
Gianelli U; Vener C; Raviele PR; Moro A; Savi F; Annaloro C; Somalvico F; Radaelli F; Franco V; Deliliers GL
Leuk Lymphoma; 2006 Sep; 47(9):1774-81. PubMed ID: 17064987
[TBL] [Abstract][Full Text] [Related]
49. Hematopathologic findings in the myeloproliferative disorders.
Dickstein JI; Vardiman JW
Semin Oncol; 1995 Aug; 22(4):355-73. PubMed ID: 7638633
[TBL] [Abstract][Full Text] [Related]
50. [Diagnosis of chronic myeloproliferative diseases based on bone marrow biopsy].
Matolcsy A; Kónya T; Wéber E
Orv Hetil; 1992 Jun; 133(26):1617-20, 1625-6. PubMed ID: 1614699
[TBL] [Abstract][Full Text] [Related]
51. Bone marrow angiogenesis: methods of quantification and changes evolving in chronic myeloproliferative disorders.
Kvasnicka HM; Thiele J
Histol Histopathol; 2004 Oct; 19(4):1245-60. PubMed ID: 15375769
[TBL] [Abstract][Full Text] [Related]
52. CD34+ stem cells in chronic myeloproliferative disorders.
Thiele J; Kvasnicka HM
Histol Histopathol; 2002 Apr; 17(2):507-21. PubMed ID: 11962756
[TBL] [Abstract][Full Text] [Related]
53. Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity.
Schmitt-Graeff A; Thiele J; Zuk I; Kvasnicka HM
Haematologica; 2002 Apr; 87(4):392-9. PubMed ID: 11940483
[TBL] [Abstract][Full Text] [Related]
54. Quantitative cytomorphology of megakaryocytes in chronic myeloproliferative disorders--analysis of planimetric and numeric characteristics by means of a knowledge based system.
Nafe R; Kaloutsi V; Fritsch RS; Georgii A
Exp Pathol; 1990; 40(4):213-9. PubMed ID: 2098268
[TBL] [Abstract][Full Text] [Related]
55. [Myeloproliferative disorders].
Binder D; Fehr J
Ther Umsch; 2004 Feb; 61(2):131-42. PubMed ID: 15018396
[TBL] [Abstract][Full Text] [Related]
56. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.
Tefferi A; Vardiman JW
Leukemia; 2008 Jan; 22(1):14-22. PubMed ID: 17882280
[TBL] [Abstract][Full Text] [Related]
57. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
Kreft A; Büche G; Ghalibafian M; Buhr T; Fischer T; Kirkpatrick CJ
Acta Haematol; 2005; 113(2):137-43. PubMed ID: 15802893
[TBL] [Abstract][Full Text] [Related]
58. Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact.
Thiele J; Kvasnicka HM; Werden C; Zankovich R; Diehl V; Fischer R
Leuk Lymphoma; 1996 Jul; 22(3-4):303-17. PubMed ID: 8819080
[TBL] [Abstract][Full Text] [Related]
59. Kinase drug discovery approaches in chronic myeloproliferative disorders.
Kumar C; Purandare AV; Lee FY; Lorenzi MV
Oncogene; 2009 Jun; 28(24):2305-13. PubMed ID: 19421140
[TBL] [Abstract][Full Text] [Related]
60. The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms.
Berzoti-Coelho MG; Ferreira AF; de Souza Nunes N; Pinto MT; Júnior MC; Simões BP; Martínez-A C; Souto EX; Panepucci RA; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2016 Jul; 59():25-30. PubMed ID: 27282563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
